VEGFA and neoplasm: In oncology, anti‐angiogenic drugs, especially those targeting the vascular endothelial growth factor (VEGF) pathway, were originally designed to inhibit the development of tumor blood vessels (“sprouting angiogenesis”) that supply growing tumors with oxygen and nutrients (Folkman, 2007; Jayson et al,2016), as well as various tumor growth‐stimulating factors (“angiocrines”) secreted by endothelial cells (Pasquier et al,2020).